Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walsh, T. R.
Right arrow Articles by MacGowan, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, T. R.
Right arrow Articles by MacGowan, A. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 357-358
© 2001 The British Society for Antimicrobial Chemotherapy

Correspondence

Detection of glycopeptide resistance in Staphylococcus aureus

T. R. Walsh*,, R. A. Howe, M. Wootton, P. M. Bennett and A. P. MacGowan

Department of Pathology and Microbiology, School of Medical Sciences, University Walk, Bristol BS8 2TD, UK

Sir,

We have a number of comments regarding the recent letter from Aucken et al.1 describing a study of the incidence of GISA (glycopeptide-intermediate Staphylococcus aureus) in the UK using a number of different methodologies at different times.

The emergence of S. aureus with reduced susceptibility to glycopeptides (particularly vancomycin), whilst a significant threat also poses interesting challenges as regards definition and detection. The prototypical strain of GISA, Mu50,2 has a vancomycin MIC of 8 mg/L and is therefore by definition resistant using BSAC breakpoint criteria (it is intermediately resistant using NCCLS criteria). A second group of isolates . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
N. J. Asha, D. Tompkins, and M. H. Wilcox
Comparative Analysis of Prevalence, Risk Factors, and Molecular Epidemiology of Antibiotic-Associated Diarrhea Due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus.
J. Clin. Microbiol., August 1, 2006; 44(8): 2785 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Bujdakova, M. Filipova, A. Liskova, and H. Drahovska
Molecular characterization of hospital vancomycin-resistant Enterococcus faecalis isolated in Slovakia
J. Antimicrob. Chemother., February 1, 2004; 53(2): 405 - 406.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. J. Manuel, A. Tuck, A. Lowes, and A. Pallett
Detection of teicoplanin resistance in UK EMRSA-17 strains
J. Antimicrob. Chemother., December 1, 2002; 50(6): 1089 - 1090.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. M. MacKenzie, P. Greig, D. Morrison, G. Edwards, and I. M. Gould
Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland
J. Antimicrob. Chemother., November 1, 2002; 50(5): 689 - 697.
[Abstract] [Full Text] [PDF]